BioMark Diagnostics Inc.
BUX
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -349.50K | -300.70K | -294.00K | -239.20K | -401.30K |
| Total Depreciation and Amortization | 62.80K | 72.60K | 158.10K | 41.80K | 42.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.60K | 11.00K | 29.00K | 21.40K | 93.90K |
| Change in Net Operating Assets | -77.80K | 10.60K | -207.90K | 40.30K | 168.90K |
| Cash from Operations | -349.80K | -206.50K | -314.90K | -135.60K | -95.80K |
| Capital Expenditure | -6.30K | -1.40K | -700.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 768.40K | -1.36M | -- | -- | -- |
| Cash from Investing | 762.10K | -1.36M | -700.00 | 0.00 | 0.00 |
| Total Debt Issued | 89.30K | 89.30K | 89.30K | 110.30K | 89.30K |
| Total Debt Repaid | -147.50K | -189.00K | -174.00K | -122.00K | -116.40K |
| Issuance of Common Stock | -- | -- | 2.93M | 255.40K | 51.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -42.20K | -72.10K | 1.98M | 174.20K | 17.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 370.00K | -1.64M | 1.67M | 38.50K | -78.20K |